Cushman & Wakefield (NYSE: CWK) recently announced the firm has represented Jay Group, a leading order fulfillment and logistics company headquartered in Lancaster, Pennsylvania, in leasing 126,916 square feet (sf) of industrial/warehouse space in Reno, Nevada.
Owned by Prologis, Inc., the global leader in logistics real estate, the facility is located at 1381 Capital Blvd and is commonly known as Prologis Reno Airport 1. Brian Armon, CCIM, SIOR with Cushman & Wakefield in Reno represented the tenant in the transaction.
Jay Group will occupy just over half of the two-tenant building totaling approximately 232,000 sf and situated in the heart of The Truckee Meadows. Jay Group has been an industry-leading provider of warehouse inventory management, eCommerce fulfillment, and specialty packaging services for more than 50 years, and the facility will serve as a distribution and fulfillment center for the company’s West Coast clients.
"This Northern Nevada facility will represent Jay Group’s first location in the Western United States,” said Brian Armon. "The company was most attracted to the Reno area as it offers a unique geographic advantage with excellent next day delivery service across the West region, providing service to nearly 70 million people.”
Armon added, "This was a great collaborative effort all around between Jay Group, Prologis and our Cushman & Wakefield team, and we couldn’t be more pleased with the results. We were able to structure a deal that was beneficial to all parties and in a great facility that suited Jay Group’s needs. The transaction also backfills a sizable industrial vacancy before the space actually hit the market.”
About Cushman & Wakefield
Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with approximately 53,000 employees in 400 offices and 60 countries. In 2019, the firm had revenue of $8.8 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services. To learn more, visit www.cushmanwakefield.com or follow @CushWake on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005712/en/
SANTA CRUZ, Calif., Oct. 26, 2020 /PRNewswire/ -- A peer-reviewed study published in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is remarkably cost-effective when compared to currently available treatments for posttraumatic stress disorder (PTSD). It is estimated that public healthcare payers or private insurers making MDMA-assisted psychotherapy available to 1,000 patients would reduce general and mental health care costs by $103.2 million over 30 years.
Lead author Elliot Marseille, Dr.P.H., M.P.P., elaborates, "MDMA-assisted psychotherapy is conducted by a licensed psychologist and trained clinician over the course of twelve sessions. The cost is not inconsiderable, but in just over three years, healthcare providers will break even on the costs of mental health and general medical care. These estimates are promising yet likely too conservative: the study did not measure the value of increased productivity or lower disability payments as patients recover and is constrained by the limited data on the long-term trajectory of PTSD. Further research will be needed to determine the full financial, personal, and societal benefits of MDMA-assisted psychotherapy for PTSD."
Berra Yazar-Klosinski, Ph.D., Head of Research Development and Regulatory Affairs for MAPS Public Benefit Corporation and co-author, notes, "A growing body of evidence suggests that MDMA-assisted psychotherapy may be more effective than currently available treatments for PTSD, a notoriously difficult-to-treat condition. Previous research has focused on safety and efficacy and indicates statistically significant improvements over psychotherapy with a control, demonstrating reduction in symptoms for 82% of participants. This study should compel healthcare providers to include MDMA-assisted psychotherapy as a covered treatment for PTSD following FDA approval."
Rick Doblin, Ph.D., Executive Director of MAPS and a study co-author, states, "The profound personal toll of PTSD can include deterioration in physical health, relationships, and ability to participate in social activities along with the anxiety, insomnia, and suicidal ideation that mark the condition. By demonstrating a return of an average of 5.5 quality-adjusted life-years over 30 years, we have shown that MDMA-assisted psychotherapy has the potential to reduce more than the personal burden of PTSD, contributing to improved health outcomes and reduced healthcare burdens for payers and providers."
The cost-effectiveness of MDMA-assisted psychotherapy from the U.S. healthcare payers' perspective was constructed with a decision-analytic Markov model to portray the costs and health benefits of treating patients with chronic, severe, or extreme, treatment-resistant PTSD. Efficacy was based on the pooled results of six randomized controlled trials with the 105 subjects who participated in Phase 2 trials and a four-year follow-up of 19 of those subjects. The model calculates expected medical costs, mortality, quality-adjusted life-years, and incremental cost-effectiveness ratio over 30 years.
NOTEThe safety and efficacy of MDMA-assisted psychotherapy is currently under investigation. This treatment has not yet been approved by the FDA, does not work for everyone, and carries risks even in therapeutic settings.
DisclaimerThe news site hosting this press release is not associated with Multidisciplinary Association for Psychedelic Studies (MAPS). It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the treatment, product or service.
About Multidisciplinary Association for Psychedelic Studies
ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. Since its founding, MAPS has raised over $100 million for psychedelic therapy and medical research and education. For more information, visit maps.org.
ABOUT MAPS PUBLIC BENEFIT CORPORATION (MAPS PBC)MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics while prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. More information about the organization is available at mapspublicbenefit.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/maps-study-mdma-assisted-psychotherapy-will-be-more-cost-effective-than-other-treatments-for-ptsd-301159940.html
Credit Suisse believes that technology stocks are only moderately expensive
Global software industry should rise at a CAGR of over 10% until 2025, with SAP well-positioned to benefit
J.P. Morgan analysts upgraded the IFX stock to “Buy” in June
Credit Suisse, the Swiss investment banking company, believes that technology stocks remain the best investing option but has advised customers to invest in tech with greater caution.
Fundamental analysis: Moderately expensive sector
The bank is concerned with the ‘dot-com-era bubble’ taking shape in the market due to increased congestion in leading tech stocks. A downfall of these mega-cap stocks in early September eased concerns about overvaluation, but high share prices prompted Credit Suisse to conduct analysis whether its clients can still trust the sector or stay away.
Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.
The Swiss bank analyzed several key metrics to ascertain the scope of indulgence in technology stocks. Tech investment as a share of gross domestic product is close to its average, as well as the share of non-residential investment.
The analysis also showed that the capital-expenditures-to-sales ratio in tech is nowhere near extended levels and is probably boosted by expected demand for 5G devices and autonomous-driving upgrades.
Credit Suisse pointed out that technology stocks are only moderately expensive when it comes to free-cash-flow yield compared with the rest of the market. Demand for technology produced similar indications, as its sales are matching their historical trend, compared to the dot-com bubble’s 12% overreach.
The bank also said speculation is higher in some areas of the sector but not near its extreme levels. Credit Suisse said “excess in tech is high” but not like it has been in the late 1990s.
However, the bank advised clients to invest more cautiously. Credit Suisse analysts cut the overweight rating for tech stocks, due to increased market congestion and elevated regulatory risks in case Biden wins the presidential election.
Furthermore, the emergence of a proven Covid-19 vaccine could prompt a “short-term reversal in some of the online trends” that boosted tech during the pandemic, the bank added.
2 German tech stock to buy in November
SAP SE (ETR: SAP) is the largest software company in Europe and one of the world’s largest listed software companies. The global software industry is expected to rise at a CAGR of over 10% until 2025.
SAP stock price is 10.7% up year-to-end with a fresh all-time high created in the last week of September. A correction has taken place since this move higher to push SAP share price to a buy zone near the 130.00 mark. Target on the upside for the buyers is 158.00, signalling a potential upside of around 20%.
Infineon Technologies AG (ETR: IFX), one of the ten largest semiconductor manufacturers in the world. It’s exposure to the emerging 5G industry is one of the key reasons behind the company’s popularity among the investors community.
Analysts at Barclays rate IFX as “Equal-weight”, while J.P. Morgan analysts upgraded the stock to “Buy” in June. Infineon printed a new all-time high this week to reflect a strong performance on the business front. Any pullback to 25.70 should be seen as an opportunity to get on the long side to target 30.00.
Credit Suisse analysts said the tech sector remains the best investing choice, however, the bank advised customers to take some money off the table. SAP and Infineon are two German tech stocks that are likely to continue moving forward in the last quarter of the year.